Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
"We're suckers for quick fixes," Emily Feivor, a registered dietician, tells PEOPLE about the claim that honey, lemon, water, ...
Weight loss is never a cakewalk, and for Mia, it was nothing less than unachievable until she found out about Mounjaro weight ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
There’s no specific recommended Mounjaro diet plan. A healthy diet with Mounjaro generally consists of fresh fruits and vegetables, whole grains, and lean proteins. Avoiding foods high in ...
A mom of two is getting her exercise by cleaning her house. It's something Melissa Floro says she didn't have the energy to ...
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
One jab that's been capturing public attention and headlines lately is Mounjaro. The Labour Party unveiled plans to ...
(Reuters) - Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback